Highlights and Quick Summary
- Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending December 30, 2019 was 1.14% (a -108.35% decrease compared to previous quarter)
- Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -118.39%
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was -6.18% (a -135.23% decrease from previous year)
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 17.54% (a 149.15% increase from previous year)
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2017 was 7.04% (a -188.89% decrease from previous year)
- Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending December 30, 2019 was -6.18% (a -9.25% decrease compared to previous quarter)
- Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -172.11% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
| 30 Dec '19 | 29 Sep '19 | 29 Jun '19 | 30 Mar '19 |
|---|---|---|---|
| -6.18% | -6.81% | 3.13% | 8.57% |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.
Most recent Selling, General and Administrative (SG&A) Expenses Growthof ABBV including historical data for past 10 years.Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.
AbbVie Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2019 | 1.14% | -13.65% | -6.02% | -6.2% | -6.18% |
| 2018 | -1.38% | 31.71% | 16.63% | 30.44% | 17.54% |
| 2017 | 16.5% | 5.5% | 2.93% | 1.33% | 7.04% |
| 2016 | -3.34% | -6.31% | -13.92% | -8.01% | -7.92% |
| 2015 | -48.01% | -7.59% | 17.61% | 9.93% | -17.31% |
| 2014 | 130.73% | 26.49% | 2.99% | 8.33% | 44.32% |
| 2013 | 2.62% | 16.22% | 12.84% | -0.8% | 7.28% |
| 2012 | – | – | -70.08% | -7.89% | -15.35% |
| 2011 | – | – | – | – | 54.29% |
| 2010 | – | – | – | – | 14.08% |
Business Profile of AbbVie Inc.
Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.